Growth hormone-secreting adenomas: Pathology and cell biology

Neurosurgical Focus

Volumn 29, Issue 4, 2010, Pages 1-6

  Lopes, M Beatriz S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Acromegaly; Animal model; Molecular genetics; Pituitary neoplasm

Indexed keywords

HUMAN GROWTH HORMONE; PROLACTIN;

ACROMEGALY; ADENOMA; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECRETION;

ACROMEGALY; ADENOMA; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROLACTIN;

EID: 78049432058     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2010.7.FOCUS10169     Document Type: Article

References (57)

1. Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, Wawrowsky K, et al: Early multipotential pituitary focal hyperpla-sia in the a-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 19:1383-1391, 2005.
2. Asa SL, Digiovanni R, Jiang J, Ward ML, Loesch K, Yamada S, et al: A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67:7505-7511, 2007.
3. Asa SL, Kovacs K, Stefaneanu L, Horvath E, Billestrup N, Gonzalez-Manchon C, et al: Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology 131:2083-2089, 1992.
4. Bale AE, Norton JA, Wong EL, Fryburg JS, Maton PN, Oldfield EH, et al: Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res 51:1154-1157, 1991.
5. Beckers A, Daly AF: The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 157:371-382, 2007.
6. Bertherat J, Chanson P, Montminy M: The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9:777-783, 1995.
7. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S: The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290-6295, 2005.
8. Byström C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B, et al: Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci U S A 87:1968-1972, 1990.
9. Cazabat L, Guillaud-Bataille M, Bertherat J, Raffin-Sanson ML: Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas. Horm Res 71:132-141, 2009.
10. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J: Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23:555-574, 2009.
11. Clayton RN, Farrell WE: Pituitary tumour clonality revisited. Front Horm Res 32:186-204, 2004.
12. Corenblum B, Sirek AM, Horvath E, Kovacs K, Ezrin C: Human mixed somatotrophic and lactotrophic pituitary adenomas. J Clin Endocrinol Metab 42:857-863, 1976.
13. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al: Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891-1896, 2007.
14. Daly AF, Tichomirowa MA, Beckers A: Genetic, molecular and clinical features of familial isolated pituitary adenomas. Horm Res 71 (Suppl 2):116-122, 2009.
15. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M, et al: Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147:4781-4791, 2006.
16. Drake WM, Berney DM, Kovacs K, Monson JP: Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur J Endocrinol 153:203-205, 2005.
17. Dworakowska D, Grossman AB: The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23: 525-541, 2009.
18. Egashira N, Minematsu T, Miyai S, Takekoshi S, Camper SA, Osamura RY: Pituitary changes in Prop1 transgenic mice: hormone producing tumors and signet-ring type gonadotropes. Acta Histochem Cytochem 41:47-57, 2008.
19. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJ, et al: Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149:1235-1242, 2008.
20. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, et al: Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 86:3097-3107, 2001.
21. Ezzat S, Horvath E, Harris AG, Kovacs K: Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79:113-118, 1994.
22. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJP, et al: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21:3190-3198, 2002.
23. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJP, Kenyon L, et al: Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24:3427-3435, 2005.
24. Felix IA, Horvath E, Kovacs K, Smyth HS, Killinger DW, Vale J: Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy. Acta Neuropathol 71:76-82, 1986.
25. Horvath E, Kovács K: The adenohypophysis, in Kovács K, Asa SL (eds): Functional Endocrine Pathology. Boston: Black well Scientific, 1991, pp 245-281.
26. Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, et al: Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47: 761-771, 1981.
27. Kontogeorgos G, Watson RE Jr, Lindell EP, Barkan AL, Farrell WE, Lloyd RV: Growth hormone producing adenoma, in DeLellis RA, Lloyd RV, Heitz PU, et al (eds): World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Endocrine Organs. Lyon: IARC Press, 2004, pp 14-19.
28. Kreutzer J, Vance ML, Lopes MBS, Laws ER Jr: Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072-4077, 2001.
29. Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR: Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. J Clin Endocrinol Metab 71:1416-1420, 1990.
30. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L: GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692-696, 1989.
31. Lloyd RV, Gikas PW, Chandler WF: Prolactin and growth hormone-producing pituitary adenomas. An immunohistochemical and ultrastructural study. Am J Surg Pathol 7:251-260, 1983.
32. Lopes MBS, Scheithauer BW, Schiff D: Pituitary carcinoma: diagnosis and treatment. Endocrine 28:115-121, 2005.
33. Mantovani G, Lania AG, Spada A: GNAS imprinting and pituitary tumors. Mol Cell Endocrinol 326:15-18, 2010.
34. Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM: Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol Endocrinol 2:606-612, 1988.
35. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517, 2009.
36. Morris DG, Musat M, Czirják S, Hanzély Z, Lillington DM, Korbonits M, et al: Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 153:143-151, 2005.
37. Neumann PE, Goldman JE, Horoupian DS, Hess MA: Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin flaments. Arch Pathol Lab Med 109:505-508, 1985.
38. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, et al: Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82-91, 2008.
39. Ozfirat Z, Korbonits M: AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol 326:71-79, 2010.
40. Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11:433-441, 1997.
41. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, et al: Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804-812, 1997.
42. Ragel BT, Couldwell WT: Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7, 2004.
43. Ruebel KH, Leontovich AA, Jin L, Stilling GA, Zhang H, Qian X, et al: Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine 29:435-444, 2006.
44. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203-216, 2007.
45. Scheithauer BW, Kovacs K, Horvath E, Roncaroli F, Ezzat S, Asa SL, et al: Pituitary carcinoma, in DeLellis RA, Lloyd RV, Heitz PU, et al (eds): World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Endocrine Organs. Lyon: IARC Press, 2004, pp 36-39.
46. Scheithauer BW, Kovacs K, Randall RV, Horvath E, Laws ER Jr: Pathology of excessive production of growth hormone. Clin Endocrinol Metab 15:655-681, 1986.
47. Shimon I, Melmed S: Acromegaly: differential diagnosis and treatment, in Wierman ME (ed): Contemporary Endocrinology. Diseases of the Pituitary: Diagnosis and Treatment. Totowa, NJ: Humana Press, 1997, pp 135-152.
48. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, et al: Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71:1421-1426, 1990.
49. Stergiopoulos SG, Abu-Asab MS, Tsokos M, Stratakis CA: Pituitary pathology in Carney complex patients. Pituitary 7: 73-82, 2004.
50. Stevenaert A, Harris AG, Kovacs K, Beckers A: Presurgical octreotide treatment in acromegaly. Metabolism 41 (9 Suppl 2): 51-58, 1992.
51. Taboada GF, Tabet AL, Naves LA, de Carvalho DP, Gadelha MR: Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience. Pituitary 12:165-169, 2009.
52. Vallar L, Spada A, Giannattasio G: Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566-568, 1987.
53. Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A: Familial acromegaly: case report and review of the literature. Pituitary 1:273-277, 1999.
54. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al: Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228-1230, 2006.
55. Weinstein LS, Yu S, Warner DR, Liu J: Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 22:675-705, 2001.
56. Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, et al: Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20-27, 1993.
57. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, et al: Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87:1262-1267, 2002.